1 / 47

New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century

New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century. David Stewart, PharmD , BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu . Disclosures.

zinnia
Download Presentation

New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21st Century David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu

  2. Disclosures Speaker’s Bureau for: Boehringer-Ingelheim Pharmaceuticals Janssen Pharmaceuticals

  3. At the conclusion of this program, the audience should be able to: • List the new oral anticoagulant medications currently approved or in the approval process by the United States Food and Drug Administration • Communicate basic principles of pharmacokinetics to other healthcare providers • Identify appropriate indications for the use of new oral anticoagulant medications • Develop patient specific plans utilizing newly approved oral anticoagulant agents for the treatment and prevention of venous thromboembolic events in various patient populations

  4. Including warfarin, how many oral anticoagulants are currently FDA approved in the United States? • One • Two • Three • Four • Five

  5. Warfarin Pros Cons Time of onset Frequent monitoring Dosing variability Numerous drug interactions • Experience • Inexpensive • Reversible • Monitoring available

  6. 21st Century • New therapies with FDA Approval • Dabigatran • Rivaroxaban • Additional emerging new therapies • Apixaban (Phase III trials complete) • Edoxaban (Phase III trials ongoing)

  7. Warfarin is an adequate medication with good data so I’ll continue to use warfarin. Warfarin has many shortcomings and I would prefer to use newer agents. I’m still a little hesitant about the newer agents because I’m unfamiliar with them. I prefer the newer agents over warfarin; however, I am concerned about the cost of new agents. I have serious concerns about the safety of newer anticoagulant medications. Which of the following best describes your opinion regarding the novel new anticoagulant medications?

  8. I routinely prescribe them I prescribe them in a limited and select group of patients I am very hesitant to prescribe them I have never prescribed them Which of the following best describes your current prescribing of dabigatran (Pradaxa®) or rivaroxaban (Xarelto®)?

  9. Clinical Pharmacology Comparison

  10. Coagulation Cascade Intrinsic Pathway (PTT) Extrinsic Pathway (PT) XII XIIa XI XIa VII VIIa IX IXa VIII XIII Warfarin Va X Xa Rivaroxan & Apixaban II IIa XIIIa Dabigatran Fibrinogen Fibrin

  11. Summary Table

  12. Monitoring vs. Measuring

  13. Measuring Dabigatran ThrombHaemost 2010;103:1116-27.

  14. Measuring Rivaroxaban & Apixaban • Role of aPTT & PT/INR • Anti-Xa Assays • Chromagenic anti-Xa assays may be useful • Different assays vary in sensitivity • Must calibrate standard curve based on drug concentration • HepTest® is not accurate for rivaroxaban (and likely apixaban) • Incubation period too long • Modified HepTest® may be useful but no current data Ther Drug Monit 2010;32:673-9.

  15. Measuring Rivaroxaban PT is sensitive (Don’t rely on INR) aPTT not sensitive Highlights peak concentrations J ThrombHaemost 2011;9:133-9.

  16. Apixaban Dabigatran Rivaroxaban Both 2 & 3 All of the above Which of the following are significantly affected by moderate/severe renal insufficiency?

  17. Clinical Utilization

  18. What are the current approved indications for dabigatran (Pradaxa®) in the United States? • Non-valvularAfib • Prevention of VTE • Treatment of VTE • All of the above

  19. Atrial Fibrillation

  20. Summary of Afib Data 1Dabigatran 150 mg BID group. 2Major bleeding per study design.

  21. RE-LY - Results *Non-inferiority margin = 1.46 New Engl J Med 2009;361:1139-51. New Engl J Med 2010;363:1875-76.

  22. RE-LYSummary • Dabigatran 110 mg BID vs. warfarin • Non-Inferior Efficacy • Lower major and overall bleeding rates • Similar GI bleeding rates • Dabigatran 150 mg BID vs. warfarin • Superior efficacy • Lower overall bleeding rates • Similar major bleeding rates • Elevated rates of GI bleeding • Both doses showed decreased ICH compared to warfarin (60-70% RRR)

  23. ROCKET-AFResults *Non-inferiority margin = 1.46 New Engl J Med 2011;365:883-91.

  24. ROCKET-AFSummary • Rivaroxaban vs. warfarin • Non-Inferior Efficacy • Similar bleeding rates • Lower ICH rates • High risk patient population (Mean CHADS2 score > 3) • TTR 55% New Engl J Med 2011;365:883-91.

  25. ARISTOTLEResults *Non-inferiority margin = 1.38 New Engl J Med 2011;365:981-92.

  26. ARISTOTLE Summary • Apixaban vs. warfarin • Superior efficacy with apixaban • ↓ overall mortality with apixaban (NNT = 238) • Lower bleeding rates with apixaban • Lower ICH rates • Apixaban vs. Aspirin • 6,000 high-risk patients (mean CHADS2 = 2) • Not candidates for warfarin • 1 year follow-up • Superior efficacy to aspirin • Similar bleeding (including ICH) rates New Engl J Med 2011;365:981-92. New Engl J Med 2011;364:806-17.

  27. Which of the following have been shown at least as effective as warfarin for the prevention of stroke in patients with atrial fibrillation? • Apixaban • Dabigatran • Rivaroxaban • Both 1 & 2 • All of the above

  28. Treatment of Acute Venous Thromboembolism

  29. True False Both dabigatran and rivaroxaban have been shown to be effective in the treatment of acute VTE.

  30. Summary of VTE Data1 1Apixaban data in VTE are not available, AMPLIFY & AMPLIFY-EXT are ongoing. 2Initial therapy in study group, both studies “bridged” control group.

  31. Prevention of Venous Thromboembolism in Orthopedic Surgery Patients

  32. Summary of Orthopedic VTE Data1 1Includes patients undergoing both TKA and THA. Most studies excluded patients with CrCl < 30 ml/min. Summary of these data available in: Pharmacother 2011;31:1175-91.

  33. VTE Prophylaxis in Medical Patients

  34. Extended Apixaban vs. Standard Enoxaparin in Medical Patients • ADOPT Trial • Medical patients at high risk for VTE (n=4,495) • Treatment Groups • Apixaban 2.5 mg BID for 30 days • Enoxaparin 40 mg SQ daily during admission • Results • No difference in primary outcome • VTE death, PE, symptomatic DVT or asymptomatic proximal DVT (0.87; 0.62-1.23) • No difference in other outcomes • Did not meet criteria for non-inferiority (Key 2˚ outcome) • Higher rate of major bleeding (2.58; 1.02-7.24) • Summary • Extended apixaban was not better than standard enoxaparin in this superiority trial • Study was underpowered by over 2,250 patients (goal of 6,758) New Engl J Med 2011;365:2167-77.

  35. Extended Rivaroxaban vs. Standard Enoxaparin • Data not yet published • 8,101 medical patients • Treatment Groups • Rivaroxaban 10 mg daily for 35 days • Enoxaparin 40 mg SQ daily for 6-14 days • Primary Outcome Reduced • 0.77 (0.62-0.96) • Increased Major & Clinically Relevant Bleeding • No net clinical benefit http://www.theheart.org/article/1207331.do

  36. Acute Coronary Syndrome

  37. ApixabanAcute Coronary Syndrome (APPRAISE-2) • Double blind, placebo controlled, RCT • ACS plus 2 additional risk factors • Apixaban • 5 mg twice daily • 2.5 mg twice daily (CrCl < 40 ml/min) • No benefit in any efficacy outcomes • Safety • Major & minor TIMI, ISTH, and GUSTO criteria bleeding was increased with apixaban • Increased fatal and intracranial bleeding • Study terminated early at 1 year New Engl J Med 2011;365:699-708.

  38. Rivaroxaban • ATLAS-ACS 2 TIMI 51 Trial • All patients received low dose ASA with either: • Rivaroxaban 2.5 mg twice daily or • Rivaroxaban 5 mg twice daily • Groups were stratified based on clopidogrel use • Large number of patients from Eastern Europe (40%); however North America data were independently consistent/significant • Results • Primary Endpoint (CV Death, MI or CVA) • Both doses better than placebo • TIMI Major Bleeding • Rivaroxaban 2.5 mg BID vs Placebo: HR = 3.46 (2.08-5.77) • Rivaroxaban 5 mg BID vs Placebo: HR = 4.47 (2.71-7.36) • Intracranial Hemorrhage • Rivaroxaban 2.5 mg BID vs Placebo: HR = 2.83 (1.02-7.86) • Rivaroxaban 5 mg BID vs Placebo: HR = 3.74 (1.39-10.07) • Summary • Improved outcomes but 3-fold increased risk of major bleeding New Engl J Med 2012;366:9-19.

  39. Dabigatran • Phase II study completed & published 2/2011 • Meta-analysis (January 2012) • 30,514 patients included • Multiple indications/populations • Majority of patients & events from RE-LY • MI vs. Warfarin • RR: 1.33 (1.03-1.71) • AR: 0.40% • Mortality vs. Warfarin • RR: 0.89 (0.80-0.99) • AR: 0.19 • Interpret in light of stroke reduction • More investigation warranted

  40. Summary

  41. Take Home Points for Providers • Several new options currently or will exist to replace warfarin • Current approved indications include: • Prophylaxis of VTE in orthopedic patients • Prevention of stroke in patients with Afib • Date also exists to support their use in: • Treatment of VTE • Agents vary based on various pharmacologic and pharmacokinetic parameters • None of the new agents require monitoring • Would base choice of agent o patient specific factors • All of them can be “measured” if needed • Best technique for reversal is unknown for most at this time • Cost will be a limitation if not covered by insurance

  42. Practical Provider Information 133% of elimination is renal and rivaroxaban does require dosage adjustment with CrCl < 50 ml/min. 2With dronedarone & ketoconazole when CrCl is 30-50 ml/min, decrease dabigatran to 75 mg BID; do not use when CrCl < 30 ml/min. 3As with any anticoagulant, adverse bleeding is still a concern. Both dabigatran and rivaroxaban demonstrated increased rates of GI bleeding, but lower rates of intracranial hemorrhage and similar overall rates of bleeding compared to warfarin.

  43. Practical Patient Information • Dabigatran • Store in original container • Discard opened product after 4 months • Dyspepsia most common side effect (up to 30%) • Do not open capsule • Comprehensive Patient Guide Available Online1 • Rivaroxaban • Ask pharmacist or physician about DDIs • At Afib dose should take with supper • Do not crush, chew, or split tablet • Overall tolerated well 1Circ 2011;124:e209-e211. (DOI: 10.1161/CIRCULATIONAHA.111.019786)

  44. I will begin routinely prescribing these agents. I may prescribe them in a limited and select group of patients. I am still very hesitant to prescribe them. I will not prescribe them at all for now. Which of the following best describes your opinion regarding prescribing of dabigatran (Pradaxa®) or rivaroxaban (Xarelto®) after this program?

  45. New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21st Century David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu

  46. Use of Concomitant Antiplatelet Agents New Engl J Med 2009;361:1139-51. New Engl J Med 2011;365:883-91. New Engl J Med 2011;365:981-92.

  47. Summary Table

More Related